Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla

Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla

Bibliographic Details
Main Authors:	Verma, Gaurav, Mohan, Suyash, Nasrallah, MacLean P., Brem, Steven, Lee, John Y. K., Chawla, Sanjeev, Wang, Sumei, Nagarajan, Rajakumar, Thomas, M. Albert, Poptani, Harish
Format:	Online
Language:	English
Published:	BioMed Central 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034563/

Similar Items

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients
by: Choi, Changho, et al.
Published: (2012)

Così lontani, così vicini
by: Scannapieco, Anna
Published: (2017-12-01)

Urine 2-Hydroxyglutarate in Glioma
by: Lombardi, Giuseppe, et al.
Published: (2016)

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
by: Pavithra Viswanath, et al.
Published: (2018-04-01)

Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
by: Fiehn, Oliver, et al.
Published: (2016)

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
by: Suijker, Johnny, et al.
Published: (2015)

Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy
by: Natsumeda, Manabu, et al.
Published: (2014)

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
by: Zoltán Hujber, et al.
Published: (2017-06-01)

D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth
by: Ma, Shenghong, et al.
Published: (2015)

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
by: Chittaranjan, Suganthi, et al.
Published: (2014)

Progress in understanding 2-hydroxyglutaric acidurias
by: Kranendijk, Martijn, et al.
Published: (2012)

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model
by: Wang, Fang, et al.
Published: (2016)

«La (per così dire) energia delle figure»
by: Bertrand Rougé
Published: (2012-05-01)

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
by: Li, Luyuan, et al.
Published: (2015)

D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH
by: Oizel, K, et al.
Published: (2015)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
by: Krell, Daniel, et al.
Published: (2011)

The sodium-dependent di- and tricarboxylate transporter, NaCT, is not responsible for the uptake of D-, L-2-hydroxyglutarate and 3-hydroxyglutarate into neurons
by: Brauburger, Katja, et al.
Published: (2011)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
by: Mondesir, Johanna, et al.
Published: (2016)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
by: DiNardo, Courtney D, et al.
Published: (2015)

IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis
by: Zou, Peng, et al.
Published: (2013)

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
by: Killela, Patrick J., et al.
Published: (2014)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
by: Wang, Hao-Yuan, et al.
Published: (2016)

Validation of the controlled ovarian stimulation impact measure (COSI): assessing the patient perspective
by: Brod, Meryl, et al.
Published: (2013)

Fast reconstruction of the elementary particle tracks for the cosy-tof experiment
by: E I Borodina
Published: (2012-09-01)

Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation
by: Koivunen, Peppi, et al.
Published: (2012)

Consequences of oncogenic isocitrate dehydrogenase mutations and 2-hydroxyglutarate production in prostate epithelium
by: Over, Jon A, et al.
Published: (2013)

An interesting case of metabolic dystonia: L-2 hydroxyglutaric aciduria
by: Balaji, Padma, et al.
Published: (2014)

Clinical, Neuroimaging, and Genetic Features of the Patients with L-2-Hydroxyglutaric Aciduria
by: Ebru Canda, et al.
Published: (2018-03-01)

Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer
by: Shim, Eun-Hee, et al.
Published: (2015)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
by: Carbonneau, Mélissa, et al.
Published: (2016)

MRI features in 17 patients with l2 hydroxyglutaric aciduria
by: Fourati, Héla, et al.
Published: (2016)

The immunometabolite S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate
by: Tyrakis, Petros A., et al.
Published: (2016)

Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
by: Gelman, Susan J., et al.
Published: (2015)

Writer’s cramp as a presentation of L-2-hydroxyglutaric aciduria
by: Termsarasab, Pichet, et al.
Published: (2014)

Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate
by: Fan, Jing, et al.
Published: (2014)

Field electron emission based on resonant tunneling in diamond/CoSi2/Si quantum well nanostructures
by: Gu, Changzhi, et al.
Published: (2012)

In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists
by: Kim, Hyeonjin, et al.
Published: (2016)

Promoter Methylation Analysis of IDH Genes in Human Gliomas
by: Flanagan, Simon, et al.
Published: (2012)

Characteristics of gliomas in patients with somatic IDH mosaicism
by: Bonnet, Charlotte, et al.
Published: (2016)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
by: Izquierdo-Garcia, Jose L., et al.
Published: (2015)